Poolbeg Pharma (LON:POLB) Hits New 12-Month High – Here’s Why

Shares of Poolbeg Pharma PLC (LON:POLB) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 5.80 and last traded at GBX 5.55, with a volume of 5824547 shares. The stock had previously closed at GBX 5.04.

Analyst Upgrades and Downgrades

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday.

Poolbeg Pharma Trading Up 3.4%

The stock has a market cap of £40.46 million, a P/E ratio of -6.10 and a beta of 1.78. The company’s fifty day simple moving average is GBX 4.52 and its 200-day simple moving average is GBX 4.32.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. As a group, analysts expect that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.